Adaptive Biotechnologies Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Adaptive Biotechnologies Corporation
Despite a recent disappointment in a similar partnership with BioNTech, Genentech is pushing ahead with its neoantigen-targeting strategy.
A two and half year-old partnership between Adaptive Biotechnologies and Microsoft that began with a focus on Lyme disease has transitioned to mapping immune responses to the SARS-CoV-2 virus. By identifying and matching T cell receptors to antigens associated with the virus – and leveraging the power of machine learning – the companies hope to improve COVID-19 vaccine development, locate potential antibodies for drug development and create better, more sensitive diagnostics.
Relay raises $400m to kick off July’s second big week of US initial public offerings. Also, Ocumension and Immunotech launch Hong Kong IPOs, Amgen invests $421m in BeiGene’s $2.08bn offering, Cytokinetics gets up to $400m in deal and investment funding, and Imvax closes $111m series C round.
- Other Names / Subsidiaries
- Adaptive TCR Corporation